Impact Analytical Expands Michigan Facility - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Impact Analytical Expands Michigan Facility



Impact Analytical’s new facility, located in Midland, Mich., has added $200,000 in instrumentation and brought on several additional analytical and business development experts to support its testing services since its opening in June 2013.

The new instrumentation gives Impact the opportunity to strengthen its core capabilities, including ICP-MS to comply with new USP methods (<232> and <233>) for heavy metals, ion chromatography, an ASE extractor for use in extractables and leachables studies, and a LC-MS Q-TOF system with exact mass capabilities.

The new site includes 35 scientists who operate more than 80 instruments in six areas, including elemental analysis, gas separation, liquid separation, microscopy, molecular characterization, and thermal and mechanical properties.

Source: Impact Analytical

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here